Profile

Business Description

Synthetic Biologics is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. Our lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), pathogenic overgrowth and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). We are also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU).

Company Info

Address:
9605 Medical Center Drive
Suite 270
Rockville, MD 20850 US

Telephone:
(301) 417-4364

Fax:
(301) 417-4367

Email:
info@syntheticbiologics.com

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

SIC:
Pharmaceutical Preparations (2834)